Electromed Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Jim Cunniff
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 34.93% |
| CEO tenure | 2.9yrs |
| CEO ownership | 1.8% |
| Management average tenure | no data |
| Board average tenure | 6.8yrs |
Recent management updates
Recent updates
Narrative Update • Jun 02
ELMD: Bronchiectasis Exposure And Margin Execution Will Support Future Upside
Analysts have nudged their price target on Electromed stock higher to $40 from $38, citing record Q3 results with 18.4% revenue growth, strong operating leverage, and confidence in continued double-digit expansion supported by broader adoption, payer coverage, and an underpenetrated bronchiectasis market. What's in the News Analysts raised their price target on Electromed stock to $40 from $38, citing record Q3 results and 18.4% revenue growth.
Narrative Update • Apr 18
ELMD: Refined Discount Rate And P/E Assumptions Will Drive Future Upside
Analysts raised their price target on Electromed by $2, reflecting updated assumptions about the discount rate, profit margin, revenue growth, and future P/E that support a slightly higher valuation framework. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as consistent with refreshed assumptions on discount rate and future P/E that leave room for upside if execution stays on track.Narrative Update • Apr 04
ELMD: Refreshed Discount Rate And P/E Assumptions Will Support Future Upside
Analysts have raised their price target on Electromed by $2, citing updated assumptions about discount rates, revenue growth, profit margins and future P/E that support a slightly higher fair value estimate. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as consistent with refreshed assumptions on discount rates and future P/E, which together suggest more support for the current valuation than before.Narrative Update • Mar 21
ELMD: Share Repurchases And Margin Execution Will Support Future Upside
Analysts have raised their price target on Electromed by $2 to reflect updated assumptions around revenue growth, profit margin and long-term P/E expectations. Analyst Commentary Recent research points to a more cautious tone around Electromed, even alongside the higher price target.Narrative Update • Mar 06
ELMD: Share Repurchases And Higher Margin Outlook Will Drive Future Upside
Analysts have increased their price target on Electromed by $2 to $36, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E as key factors behind the change. Analyst Commentary While the new US$36 price target reflects updated valuation work, some bearish analysts are still flagging risk factors that they believe limit upside for Electromed at current levels.Narrative Update • Feb 20
ELMD: Share Repurchases Will Support Future Upside In Undervalued Shares
Analysts have nudged their price target on Electromed up by $1 to $37, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E after the latest Street research. Analyst Commentary Recent Street research has focused on how Electromed's fundamentals line up with the revised fair value assumptions and the updated $37 target.Narrative Update • Feb 06
ELMD: Completed Share Buyback Will Support Future Upside In Undervalued Shares
Analysts have adjusted their price target on Electromed to reflect a fair value of $36.00, citing only minor tweaks to assumptions around the discount rate, revenue growth, profit margin and future P/E. Their overall valuation view remains largely unchanged.Narrative Update • Jan 21
ELMD: Share Buyback And Higher Margin Outlook Will Support Future Upside
Analysts have kept their price target for Electromed steady at US$34.00, reflecting updated views on slightly higher projected revenue growth and profit margins, along with a marginally adjusted discount rate and future P/E assumption. What's in the News Completed the repurchase of 40,848 shares, representing 0.49% of the company, for US$1 million under the share buyback announced on September 9, 2025 (Key Developments).Narrative Update • Jan 07
ELMD: Higher Margin Outlook And Share Buyback Will Support Upside Potential
Analysts have raised their fair value estimate for Electromed from US$29 to US$34, citing updated assumptions around revenue growth, profit margins, and a lower future P/E multiple as key drivers of the change. What's in the News Between September 9, 2025 and September 30, 2025, Electromed repurchased 40,848 shares for US$1 million, representing 0.49% of shares.Narrative Update • Dec 15
ELMD: Share Repurchase Program Will Support Future Upside In Undervalued Shares
Analysts have nudged their price target for Electromed slightly higher to approximately $36.00 per share, citing modest improvements in discount rate assumptions and forward valuation metrics while largely reaffirming their prior outlook. What's in the News Completed a share repurchase tranche totaling 40,848 shares, or about 0.49 percent of outstanding shares, for approximately $1 million under the buyback program announced September 9, 2025 (company filing) Valuation Changes Fair Value Estimate reaffirmed at approximately $36.00 per share, reflecting no material change in intrinsic value assumptions.Narrative Update • Nov 30
ELMD: Share Repurchase Plan And Expanding Outlook Will Lift Share Price
Analysts have raised their price target for Electromed from $35.25 to $36.00. They cite an improved outlook for future revenue growth, despite a slightly higher discount rate and marginally lower profit margin projections.Narrative Update • Nov 16
ELMD: Double-Digit Revenue Gains And Buybacks Will Drive Shares Higher
Electromed's analyst fair value target increased slightly from $35.00 to $35.25, as analysts cite consistent double-digit revenue growth forecasts and improving operational efficiency in recent reports. Analyst Commentary Bullish Takeaways Bullish analysts highlight Electromed's consistent double-digit revenue growth forecasts and note that ongoing top-line expansion is expected in the coming years.
New Narrative • Feb 21
The Triple Down On Bronchiectasis Campaign Will Expand SmartVest Clearway's Market Reach
Diversifying beyond homecare and investing in sales efforts may drive revenue growth and improve earnings through expanded market channels and effective sales execution.CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$10m |
| Dec 31 2025 | n/a | n/a | US$9m |
| Sep 30 2025 | n/a | n/a | US$8m |
| Jun 30 2025 | US$1m | US$519k | US$8m |
| Mar 31 2025 | n/a | n/a | US$7m |
| Dec 31 2024 | n/a | n/a | US$7m |
| Sep 30 2024 | n/a | n/a | US$6m |
| Jun 30 2024 | US$3m | US$500k | US$5m |
Compensation vs Market: Jim's total compensation ($USD1.49M) is below average for companies of similar size in the US market ($USD2.59M).
Compensation vs Earnings: Jim's compensation has been consistent with company performance over the past year.
CEO
Jim Cunniff (60 yo)
2.9yrs
Tenure
US$1,486,329
Compensation
Mr. James L. Cunniff, also known as Jim, serves as an Independent Director at Avanos Medical Inc. since April 21, 2026. He serves as the President and Chief Executive Officer at Electromed, Inc., since Jul...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.6yrs | US$1.49m | 1.78% $ 5.4m | |
| Independent Director | 6.8yrs | US$141.34k | 0.25% $ 771.1k | |
| Chairman | 12.6yrs | US$158.84k | 0.43% $ 1.3m | |
| Independent Director | 3.9yrs | US$136.34k | 0.11% $ 330.5k | |
| Lead Independent Director | 4.6yrs | US$166.84k | 0.18% $ 550.8k | |
| Independent Director | 5.6yrs | US$139.34k | 0.22% $ 661.0k | |
| Independent Vice Chairman of the Board | 11.6yrs | US$144.34k | 0.47% $ 1.4m | |
| Independent Director | 4.6yrs | US$134.34k | 0.18% $ 550.8k | |
| Member of Bronchiectasis Advisory Board | 8.8yrs | no data | no data | |
| Member of Bronchiectasis Advisory Board | 8.8yrs | no data | no data | |
| Member of Bronchiectasis Advisory Board | 8.8yrs | no data | no data |
6.8yrs
Average Tenure
62yo
Average Age
Experienced Board: ELMD's board of directors are considered experienced (6.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/05 04:46 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Electromed, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyle Bauser | B. Riley Securities, Inc. |
| Anderson Schock | B. Riley Securities, Inc. |
| Ilya Zubkov | Freedom Broker |